B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Orthopedic / Regulatory Affairs
Robert Cohen of Stryker Named Chair of AdvaMed’s Digital Health Tech Division Board of Directors
January 5, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Robert Cohen, vice president, innovation and technology, orthopaedic group at Stryker, will be the next chair of the AdvaMed Digital Health Tech Board of Directors. He succeeds Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare, who served as the inaugural chair of the board overseeing the then-newly created division.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Orthopedic / Regulatory Affairs / Small Business
Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors
December 11, 2025
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced Michael “Mick” Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026.
Event / Regulatory Affairs
Medical Device Submissions Workshop Series: Investigational Device Exemption (IDE)
8:30 am – 5:15 pm ET
February 25, 2026
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
Event / Regulatory Affairs
Medical Device Submissions Series: Premarket Approval (PMA) Workshop
8:30 am – 4:30 pm ET
February 26-27, 2026
Learn key PMA Submissions strategies to build a strong submissions, align with FDA expectations, and reduce delays.
Event / Regulatory Affairs
Medical Device Submissions Series: 510(k) & De Novo Workshop
Now available to purchase!
Join industry leaders for the in-depth 510(k) & De Novo Workshop for real-world case studies, submissions tips and best practices.
News / Government & Legislative Affairs / Health Access / Regulatory Affairs
AdvaMed Urges CMS to Protect Patient Access to Critical Medical Equipment
November 30, 2025
WASHINGTON — AdvaMed, the medtech association, the world’s largest trade association representing medtech innovators, today released the following statement on the U.S. Centers for Medicare & Medicaid Services’ (CMS) release of its 2026 Home Health Prospective Payment System final rule:
Event / Regulatory Affairs
QMSR Transition: Legal and Audit Perspectives
December 9, 2025
11:00 AM – 12:00 PM
Join Hogan Lovells experts to learn how the FDA is set to reshape the medical device regulatory landscape with the introduction of the QMSR.
News / China / Global & Trade / Supply Chain / Tariffs
AdvaMed Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
November 3, 2025
WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.